SciBase

We’re happy to announce SciBase participation in this year’s upcoming Cosmetotest! Join us in Lyon on the 14th and 15th of May, a great opportunity to learn more about #Nevisense and it’s abilities in cosmetic testing. #scibase #nevisense #cosmetotest2025 #beautytesting #clinicaltrials #cosmetinLyon

The Mayo Clinic is conducting a pilot study of SciBase’s Nevisense. https://lnkd.in/d4Rxn63q

We are happy to announce that The Mayo Clinic, the leading U.S. hospital, will initiate a pilot with Nevisense for AI-driven pigmented lesion workflows! Nevisense is the only FDA-approved device for point-of-care skin cancer detection in the U.S. Read the press release in full: https://lnkd.in/dBRQy9Ts #SkinCancerDetection #AI #Nevisense #Dermatology #scibase #earlydetection

Today, December 27, 2024, is the first day of the subscription period in SciBase Holding AB's rights issue of units, consisting of new shares and warrants. Over the past year, SciBase has advanced its positions significantly and the rights issue will lay the foundation for continued growth and innovation. Subscription Period: December 27, 2024 – January 13, 2025  For more information and terms: https://lnkd.in/d22DqgKw #SciBase #Innovation #Growth #RightsIssue #Nevisense

SciBase CEO Pia Renadin reflects on an impactful 2024 in this final CEO letter of the year, highlighing SciBase's strengthened position through a newly established U.S. organization, success in the skin barrier segment, and strategic expansion into new markets. These achievements have not only laid a solid foundation for continued growth but also reinforced the company's mission to reduce patient suffering and save lives. Read the letter from the CEO in full: https://lnkd.in/dN_hCH47 #scibase #nevisense #growth #skinhealth

At the MEIDAM Congress 2024 alongside our distributor Al Shirawi Healthcare Solutions. Together, we are dedicated to advancing early melanoma detection across the UAE. #nevisense #sciBase #melanomadetection #earlydetectionmatters #skinhealth #meidam2024 #meidam

Meet KILABS, our new Italian distributor and a valued extension of the SciBase team! With a focus on AI-driven advancements in dermatology, Kilabs shares our vision of revolutionizing melanoma management and elevating patient care. Together, we’re committed to bringing innovative solutions that set new healthcare standards in Italy! Pictured here is Michelangelo Simonelli (center), CEO of Kilabs, alongside his team showcasing Nevisense at the Health Innovation Show 2024 in Rome. #scibase #nevisense #innovation #skinhealth #earlydetection

The Nevisense Booth has been busy this morning! The SDPA attendees are highly engaged with Laura and Michelle, learning all about the power of EIS and augmented intelligence to test ambiguous lesions suspicious of melanoma! If you are attending the conference, make sure to stop by Booth #202 #SDPA #SDPA2024 #dermatology #melanoma #melanomadetection #skincancer #skinhealth

SciBase's Q3 2024 Interim Report reveals strong growth in the US market. Electrode sales surged by 290% and total sales increased by 187% Read the report: https://lnkd.in/dHg4JzdN #growth #innovation #SciBase #nevisense #Q3Report2024 #skinhealth

SciBase is back in Las Vegas this week! Nevisense has arrived at the #SDPA Society of Dermatology Physician Assistants Meeting. If you are attending, come visit us at Booth #202 Let’s discuss how the power of Electrical Impedance Spectroscopy combined with Augmented Intelligence (correlated with the Gold Standard) can help you elevate patient care! 🙌🏼 #Nevisense #SciBase #melanoma #melanomadetection #EIS #AI #dermatology